drugset / Trial / NCT06221111
Comparison of Rimegepant and Placebo for Pain in IBS
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary aim of this study is to evaluate the efficacy of rimegepant on abdominal pain scores in participants with non-constipation IBS.
Timeline
- Start
- 2024-06-06
- Primary completion
- 2025-05-30
- Completion
- 2025-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rimegepant | Small molecule | 75 mg | Oral |